You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!Submit Review
Blocker of the slow delayed rectifier K+ current (IKs) (IC50 = 1-10 μM). Also blocks the CFTR chloride current (ICFTR) (IC50 = 19 μM).
Enantiomer also available.
|Storage||Store at RT|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions
The following data is based on the product molecular weight 324.39. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||3.08 mL||15.41 mL||30.83 mL|
|5 mM||0.62 mL||3.08 mL||6.17 mL|
|10 mM||0.31 mL||1.54 mL||3.08 mL|
|50 mM||0.06 mL||0.31 mL||0.62 mL|
References are publications that support the biological activity of the product.
Bachmann et al (2001) Chromanol 293B, a blocker of the slow delayed rectifier K+ current (IKS), inhibits the CFTR Cl- current. Naunyn Schmiedebergs Arch.Pharmacol. 363 590 PMID: 11414653
Fujisawa et al (2000) Time-dependent block of the slowly activating delayed rectifier K+ current by chromanol 293B in guinea-pig ventricular cells. Br.J.Pharmacol. 129 1007 PMID: 10696102
Sun et al (2001) Chromanol 293B inhibits slowly activating delayed rectifier and transient outward currents in canine left ventricular myocytes. J.Cardiovasc.Electrophysiol. 12 472 PMID: 11332571
If you know of a relevant reference for Chromanol 293B, please let us know.
View Related Products by Target
View Related Products by Product Action
Keywords: Chromanol 293B, Chromanol 293B supplier, IKs, blockers, blocks, ICFTR, Potassium, KV, Channels, voltage-gated, voltage-dependent, K+, Cl-, chloride, Chromanol293B, Voltage-Gated, CFTR, 1412, Tocris Bioscience
5 Citations for Chromanol 293B
Citations are publications that use Tocris products. Selected citations for Chromanol 293B include:
Gage and Kobertz (2004) KCNE3 truncation mutants reveal a bipartite modulation of KCNQ1 K+ channels. J Gen Physiol 124 759 PMID: 15572349
Inagaki et al (2019) Involvement of butyrate in electrogenic K+ secretion in rat rectal colon. Pflugers Arch 471 313 PMID: 30250967
Neal et al (2011) Renal defects in KCNE1 knockout mice are mimicked by chromanol 293B in vivo: identification of a KCNE1-regulated K+ conductance in the proximal tubule. J Physiol 589 3595 PMID: 21576273
Yu et al (2014) Apamin does not inhibit human cardiac Na+ current, L-type Ca2+ current or other major K+ currents. J Cell Mol Med 9 e96691 PMID: 24798465
McCallum et al (2011) The contribution of Kv7 channels to pregnant mouse and human myometrial contractility. Mol Pain 15 577 PMID: 20132415
Do you know of a great paper that uses Chromanol 293B from Tocris? Please let us know.
Reviews for Chromanol 293B
Average Rating: 5 (Based on 1 Review.)
Have you used Chromanol 293B?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Chromanol 293B was used to assess how it regulates the gating kinetics of Kv2.1. The blocking action exhibited by the product was measured on epithelial Kv2.1 channels.
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* or download your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Epilepsy is a brain disease that affects 60 million people globally. More than 20 anti-seizure drugs are currently available, but these do not address the underlying causes of the condition. This poster summarizes current knowledge about the development of the condition and highlights some approaches that have disease-modifying effects in proof-of-concept studies.
Peripheral sensitization is the reduction in the threshold of excitability of sensory neurons that results in an augmented response to a given external stimulus. This poster outlines the excitatory and inhibitory signaling pathways involved in modulation of peripheral sensitization. The role of ion channels, GPCRs, neurotrophins, and cytokines in sensory neurons are also described.